Drug intelligence / Profile preview

rhinoebastel

Development stage: Unknown
Lead developer: Almirall
Modality: Small Molecules
Administration: Oral

Overview

Rhinoebastel is an oral combination drug containing ebastine (an antihistamine) and pseudoephedrine (a nasal decongestant). It is indicated for the relief of nasal and ocular symptoms associated with seasonal allergic rhinitis when accompanied by nasal congestion. Ebastine acts as a selective second-generation H1 histamine receptor antagonist, reducing allergy symptoms such as sneezing, runny nose, and itchy eyes by blocking peripheral histamine receptors. Pseudoephedrine is a sympathomimetic agent that relieves nasal congestion through vasoconstriction of the blood vessels in the nasal mucosa. The product is intended for adults and adolescents aged 12 years or older[2][8].

Brand names: RhinoebastelRino-EbastelEbastel Rhino
Other names: ebastine/pseudoephedrine

Targets

ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on rhinoebastel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rhinoebastel.

Explore the full profile